Stompor Monika, Świtalska Marta, Podgórski Rafał, Uram Łukasz, Aebisher David, Wietrzyk Joanna
Faculty of Medicine, Centre for Innovative Research in Medical and Natural Sciences, University of Rzeszów, Rzeszów, Poland.
Department of Biochemistry, Faculty of Medicine, University of Rzeszów, Rzeszów, Poland.
Acta Biochim Pol. 2017;64(3):577-583. doi: 10.18388/abp.2017_1608. Epub 2017 Aug 12.
Isoxanthohumol (2) and its 4'-O-monoacylated (3) and 7,4'-O-diacetylated (4) derivatives were synthesized and evaluated in vitro for their cytotoxic activity against several cancer cell lines of various origins: MCF-7 (breast), A549 (lung), MESSA (uterine sarcoma), LoVo (colon), drug-resistant human cancer cells (MESSA/DX and LoVo/DX), glioblastoma (U-118 MG), and also towards the non-cancerous cell line MCF-10A (normal breast cells). An antiproliferative assay indicates that 7,4'-di-O-acylisoxanthohumol (4) has similar cytotoxicity to its precursor, isoxanthohumol (2), against selected cell lines (A549, MES-SA, MES-SA/5DX, and U-118 MG). Compound 4 was only slightly more cytotoxic to lung, colon, breast (cancerous and normal) and uterine sarcoma (drug sensitive and drug resistant) cell lines compared to its monoacylated derivative (3). Both acylated isoxanthohumols showed preferential activity against tumor cells (MCF-7) and low cytotoxicity to normal cells (MCF-10A), which suggests selectivity of the acylated isoxanthohumols towards cancer cells. Additionally, the activity of the acylated isoxanthohumols was higher than for 2. To the best of our knowledge this is the first report on bioactivity of monoacylated isoxanthohumol (3) and its ester derivatives as antiproliferative compounds in drug resistant cell cultures. Acylation of 2 decreased the antioxidant activity determined by the DPPH method in the order isoxanthohumol (2) >4'-O-acetylisoxanthohumol (3) >7,4'-di-O-acetylisoxanthohumol (4).
合成了异黄腐酚(2)及其4'-O-单酰化衍生物(3)和7,4'-O-二乙酰化衍生物(4),并在体外评估了它们对多种来源的几种癌细胞系的细胞毒性活性:MCF-7(乳腺癌)、A549(肺癌)、MESSA(子宫肉瘤)、LoVo(结肠癌)、耐药性人类癌细胞(MESSA/DX和LoVo/DX)、胶质母细胞瘤(U-118 MG),以及对非癌细胞系MCF-10A(正常乳腺细胞)。抗增殖试验表明,7,4'-二-O-酰基异黄腐酚(4)与其前体异黄腐酚(2)对选定细胞系(A549、MES-SA、MES-SA/5DX和U-118 MG)具有相似的细胞毒性。与单酰化衍生物(3)相比,化合物4对肺癌、结肠癌、乳腺癌(癌性和正常)和子宫肉瘤(药物敏感和耐药)细胞系的细胞毒性仅略高。两种酰化异黄腐酚均对肿瘤细胞(MCF-7)表现出优先活性,对正常细胞(MCF-10A)的细胞毒性较低,这表明酰化异黄腐酚对癌细胞具有选择性。此外,酰化异黄腐酚的活性高于化合物2。据我们所知,这是关于单酰化异黄腐酚(3)及其酯衍生物作为耐药细胞培养中抗增殖化合物的生物活性的首次报道。2的酰化按异黄腐酚(2)>4'-O-乙酰基异黄腐酚(3)>7,4'-二-O-乙酰基异黄腐酚(4)的顺序降低了用DPPH法测定的抗氧化活性。